Aktienanalyse zu Electromed Inc (ELMD)ELMDElectromed Inc

Electromed, Inc. develops, manufactures, markets and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function. It applies High Frequency Chest Wall Oscillation (HFCWO) technologies in pulmonary care for patients of all ages. The SmartVest Clearway System consists of an inflatable therapy garment, a programmable air pulse generator and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall. The SmartVest Clearway is designed for comfort and convenience, so patients can readily fit therapy into their daily routines. The SmartVest System is primarily prescribed for patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis. It also markets the Single Patient Use (SPU) SmartVest and SmartVest Wrap to health care providers in the acute care setting. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Electromed Inc is a good buy right now due to its current price of $26.76, which is significantly below the analyst price target range of $40 to $47, indicating substantial upside potential. Additionally, the company reported a gross margin of 78.71% in Q4 2026, demonstrating strong profitability. The primary risk is the RSI of 40.024, suggesting the stock may be approaching oversold conditions, which could lead to short-term volatility.